# Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

> **NCT02609945** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 21 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** zolmitriptan
- **DRUG:** CVT-427 (zolmitriptan inhalation powder),

## Key facts

- **NCT ID:** NCT02609945
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2015-12
- **Final completion:** 2016-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609945, "Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02609945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*